Skip to main content

Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)

Tipranks - Tipranks - Fri Mar 6, 6:14AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veeva Systems (VEEV – Research Report), Apellis Pharmaceuticals (APLS – Research Report) and AnaptysBio (ANAB – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Veeva Systems (VEEV)

In a report released today, David Grossman from Stifel Nicolaus maintained a Buy rating on Veeva Systems, with a price target of $245.00. The company’s shares closed last Wednesday at $188.48.

According to TipRanks.com, Grossman is a 3-star analyst with an average return of 1.1% and a 46.2% success rate. Grossman covers the Technology sector, focusing on stocks such as International Business Machines, Automatic Data Processing, and Exlservice Holdings. ;'>

Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $268.67, implying a 44.1% upside from current levels. In a report issued on February 19, TipRanks – xAI also upgraded the stock to Buy with a $200.00 price target.

See the top stocks recommended by analysts >>

Apellis Pharmaceuticals (APLS)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $37.00. The company’s shares closed last Wednesday at $19.86.

According to TipRanks.com, Rama is a 5-star analyst with an average return of 19.9% and a 51.6% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. ;'>

Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $31.57, implying a 55.4% upside from current levels. In a report issued on February 24, Needham also maintained a Buy rating on the stock with a $28.00 price target.

AnaptysBio (ANAB)

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on AnaptysBio, with a price target of $85.00. The company’s shares closed last Wednesday at $60.55.

According to TipRanks.com, CFA is a 5-star analyst with an average return of 31.6% and a 66.5% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Dianthus Therapeutics. ;'>

AnaptysBio has an analyst consensus of Strong Buy, with a price target consensus of $86.83, a 54.8% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $58.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).